Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Real-worldevaluatie in PATH-project werpt licht op ontwikkeling moleculair testen
nov 2022 | Longoncologie